secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2022-04-04T23:59:59+00:00
Accession:  0001193125-22-094409
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam's vutrisiran PDUFA delayed 3 months to July 14, 2022 on packaging facility issue
--------------------------------------------------------------------------------

- FDA extended review to July 14, 2022 due to amendment addressing inspection classification at third-party packaging/labeling facility.
- New secondary packaging and labeling facility identified and submitted to FDA; no inspection observations directly related to vutrisiran.
- No additional clinical data requested by FDA; vutrisiran under concurrent review by EMA, ANVISA, and PMDA.
- Alnylam aims to minimize impact on other regulatory reviews through timely resolution or alternative facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/0001193125-22-094409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000119312522094409/d259809d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-094409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer